Puma Biotechnology (PBYI) EBT (2010 - 2026)
Puma Biotechnology's (PBYI) quarterly EBT came in at -$3.4 million in Q1 2026, down 204.9% YoY from $3.3 million in Q1 2025, and down 120.03% on a QoQ basis from $17.1 million in Q4 2025.
Puma Biotechnology (PBYI) EBT (2010 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 17 years of EBT data on file, last reported at -$3.4 million in Q1 2026.
- Quarterly EBT fell 204.9% year-over-year to -$3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.1 million (up 269.98% YoY) and the FY2025 annual result came in at $35.8 million, changed N/A from the prior year.
- EBT fell to -$3.4 million in Q1 2026, from $17.1 million in the prior quarter.
- In the past five years, EBT ranged from a high of $20.6 million in Q3 2024 to a low of -$11.9 million in Q4 2024.
- A 5-year average of $3.3 million and a median of $2.3 million in 2023 frame the typical range for EBT.
- Annual changes were most pronounced in 2023 — EBT surged 2150.85% — and 2024, when it slumped 396.83%.
- Tracing PBYI's EBT over 5 years: stood at -$5.3 million in 2022, then jumped by 341.04% to $12.8 million in 2023, then slumped by 192.64% to -$11.9 million in 2024, then jumped by 244.22% to $17.1 million in 2025, then tumbled by 120.03% to -$3.4 million in 2026.
- The last three EBT figures came in at -$3.4 million (Q1 2026), $17.1 million (Q4 2025), and $9.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 8.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.25 Mn |
| Mar 31, 2026 | -3.43 Mn |
| Dec 31, 2025 | 17.11 Mn |
| Sep 30, 2025 | 9.24 Mn |
| Jun 30, 2025 | 6.17 Mn |
| Mar 31, 2025 | 3.27 Mn |
| Dec 31, 2024 | -11.86 Mn |
| Sep 30, 2024 | 20.61 Mn |
| Jun 30, 2024 | -4.15 Mn |
| Mar 31, 2024 | -4.60 Mn |
| Dec 31, 2023 | 12.80 Mn |
| Sep 30, 2023 | 6.01 Mn |
| Jun 30, 2023 | 2.31 Mn |
| Mar 31, 2023 | 1.55 Mn |
| Dec 31, 2022 | -5.31 Mn |
| Sep 30, 2022 | -293,000.00 |
| Jun 30, 2022 | 9.43 Mn |
| Mar 31, 2022 | -3.37 Mn |
| Dec 31, 2021 | 4.44 Mn |
| Sep 30, 2021 | -44.64 Mn |